I think the high volume dump at the open could be in sympathy with the blowup in BLRX today due to failure of CLARITY Trial of BL-1020 for Schizophrenia. I would have thought this a positive for Omer's PDE10. I invested in this stock due to the promising and big potential in their pipeline with MASP-2, PDE, GPCR, Plasmin, and PPAR candidates. But there is clearly deteriorating confidence in management’s ability to advance their pipeline into meaningful clinical trials or partnerships. They did not even hold a conference call in conjunction with their quarterly release. Talk about isolating the analyst and investor community. I'm sure many are not happy with the NDA for 302 being pushed out a quarter. We need an explanation please!
I am willing to ride this out a little longer, maybe until end June. Back in the December Oppenheimer Healthcare conference the CEO stated they were in active partnership discussions on most of their clinical candidates, but I am starting to have doubts. I wish they would have dropped their ACL repair trials, due to limited resources, and focused on advancing their earlier stage pipeline. I don’t even really care about their surgical products, but 302 does have decent revenue potential. If I don’t see progress in the following programs, I will take what’s left of my money and move on. They need to get data out and get IND approval for Phase 1 of MASP-2 and start Phase 2 of PDE10 in Schizophrenia. They need to establish partnership on one or more GPCR targets and also PDE. And finally get NDA and MMA filed and accepted for 302. If they can hit these goals, it should bring investor confidence back. If not, this stock will continue to be a bull trap and money pit of unfulfilled promises.